TOKYO—Kuno Keisuke, the Vice President of the CX Division at HeartCore Enterprises, Inc. (NASDAQ:HTCR), executed a series of stock sales on November 19, 2024. According to a recent SEC filing, Keisuke sold a total of 26,000 shares of common stock, generating proceeds of approximately $32,980. These transactions were completed at prices ranging from $1.26 to $1.28 per share. The stock, which InvestingPro analysis indicates is currently overbought, has seen a remarkable 14.67% gain in the past week, with the current price at $1.72.
Following these sales, Keisuke retains direct ownership of 75,785 shares in the company. HeartCore Enterprises, based in Tokyo, operates in the computer processing and data preparation services industry. The company, with a market capitalization of $35.38 million, has demonstrated strong financial performance with 47.63% revenue growth and trades at a P/E ratio of 6.06. InvestingPro subscribers can access 8 additional key insights about HTCR's financial health and growth prospects.
In other recent news, HeartCore Enterprises has confirmed its compliance with the Nasdaq's minimum bid price requirement, securing its continued listing on the Nasdaq Capital Market. This development followed a significant shift towards a Software (ETR:SOWGn) as a Service (SaaS) model for its content management system platform, which is expected to drive a 115% sales growth. The company forecasts Q3 2024 revenues between $17 million and $19 million, marking a noteworthy year-over-year increase. HeartCore has also entered into collaborations with Tosho Computer Systems Co., Ltd. and Fourmix Co., Ltd. aimed at boosting sales of its investor relations support tool, irVision, and integrating its Content Management System platform into Fourmix's operations. Additionally, HeartCore reported substantial revenue from SBC Medical (TASE:PMCN) Group Holdings Inc.'s initial public offering and at the company's annual virtual meeting of stockholders, all six nominees for the Board of Directors were elected to serve a one-year term and a reverse stock split of HeartCore's common stock was approved.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.